This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
<i>Staphylococcus</i>	CC chemokine receptor 5 (CCR5; CD195)	Cell culture and mouse studies suggest inhibiting CCR5 could help treat <i>Staphylococcus aureus</i> infections. <i>In vitro</i> , <i>S. aureus</i> leukotoxin killed CCR5-expressing cell lines. The effect was blocked with multiple small molecule CCR5 antagonists. In a model of <i>S. aureus</i> systemic infection, <i>Ccr5</i> knockout mice had lower bacterial load and greater survival than wild-type mice. Next steps include developing animal models that can monitor the efficacy of CCR5 antagonists. Pfizer Inc. markets the CCR5 antagonist Selzentry maraviroc to treat HIV/AIDS.	Patent application filed; licensing status undisclosed	Alonzo, F. III <i>et al.</i> <i>Nature</i> ; published online Dec. 12, 2012; doi:10.1038/nature11724 Contact: Victor J. Torres, New York University School of Medicine, New York, N.Y. e-mail: victor.torres@nyumc.org
<i>SciBX</i> 6(1); doi:10.1038/scibx.2013.15 Published online Jan. 10, 2013				